GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Endoscopy/Novel Catheter Improves Endoscopic Transpapillary Gallbladder Drainage in Malignant Biliary Stricture VideoGIE | July 2026
29

Novel Catheter Improves Endoscopic Transpapillary Gallbladder Drainage in Malignant Biliary Stricture VideoGIE | July 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated July 1, 2026

Introduction: Acute cholecystitis in patients with malignant biliary obstruction can be difficult to manage, particularly when surgery is not feasible. Endoscopic transpapillary gallbladder drainage (ETGBD) is an attractive minimally invasive option, but selective cannulation of the cystic duct remains technically challenging. This video case demonstrates the use of a novel ETGBD catheter to facilitate successful gallbladder drainage.

Why was this technique needed?

  • ETGBD is technically demanding because of difficult cystic duct cannulation.
  • Malignant biliary strictures further reduce the success of conventional drainage.
  • Many patients are poor surgical candidates.
  • Safer and more reliable endoscopic accessories are needed.
  • Improved devices may increase the success of minimally invasive gallbladder drainage.

Key Technical Points:

  • A novel dedicated catheter enabled successful navigation through the cystic duct despite malignant distal biliary obstruction.
  • The device facilitated successful endoscopic transpapillary gallbladder drainage, avoiding the need for percutaneous drainage or surgery.
  • The technique demonstrates the potential of specialized accessories to improve the technical success of ETGBD in complex biliary anatomy.

Clinical Impact:

Endoscopic transpapillary gallbladder drainage is an important alternative for patients with acute cholecystitis and malignant biliary obstruction. The availability of dedicated devices may simplify technically difficult procedures, expand the applicability of ETGBD, and reduce dependence on percutaneous drainage.

Bottom Line:

Novel ETGBD accessories can improve the success of endoscopic gallbladder drainage in patients with malignant biliary strictures. As dedicated devices continue to evolve, ETGBD may become an increasingly practical minimally invasive option for high-risk patients.

Related Q&A

30

AI for Early Esophageal Cancer Detection: AJG | July 2026

Introduction: Early detection of esophageal squamous cell carcinoma (ESCC) is critical for curative endoscopic treatment. However, subtle lesions are often missed during routine endoscopy. This meta-analysis evaluated whether...

31

EndoBarrier Improves Diabetes and Weight Loss: Ann Surg | July 2026

Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal...

32

Immediate Endoscopic Necrosectomy in Necrotizing Pancreatitis: Gastroenterology | July 2026

Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains...

33

Endoscopy After Bevacizumab Appears Safe: GIE | July 2026

Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns...

34

Colorectal ESD Perforation: Endoscopy | July 2026

Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large...

35

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity,...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer